SUMMARY -Th e aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistant indolent NHL and CLL in patients not fi t for conventional chemotherapy. Recent studies have shown superiority of bendamustine combination with rituximab (B-R) in fi rst line treatment of indolent NHLs and mantle cell lymphoma, suggesting a shift of the standard of care in this setting. B-R regimen has also shown effi cacy in relapsed setting suggesting the possible treatment option for patients failing conventional chemotherapy. In rituximab-resistant NHL, the recent GADOLIN study exploring the addition of obinutuzumab to bendamustine has yielded impressive result changing the standard of care in this hard-to-treat population. Concerning CLL, despite inferiority to the standard of care in young fi t patients, as defi ned in CLL10 study, B-R has yielded a more benefi cial toxicity profi le and its use in fi rst line treatment should be decided individually. In relapsed setting, the addition of ibrutinib to B-R has shown superior results compared to B-R alone, possibly changing the paradigm of treatment of relapsed CLL. In conclusion, bendamustine as a single agent or in combinations has shown activity with acceptable toxic profi le in the treatment of patients with indolent NHLs or CLL without del(17p) mutation.
Introduction
Non-Hodgkin lymphomas (NHL) represent the most common malignancy in hematologic oncology. According to the US SEER program, its incidence is 19.5 cases per 100 000 men and women, with 70.7% of patients surviving for 5 years 1 . Chronic lymphocytic leukemia (CLL) is the most common leukemia of elderly with the incidence of 4.6 cases per 100 000 men and women, with 82.6% of patients surviving for 5 years according to the SEER program 2 . In Croatia, the incidence of NHL is estimated to 6.96 per 100 000 men and 5.57 per 100 000 women 3 . Th e incidence of CLL is 2.59 per 100 000 men and 1.2 per 100 000 women. It is important to note that NHLs are heterogeneous disorders varying from aggressive type such as diff use large B cell lymphoma (DLBCL) to in dolent one such as follicular lymphoma (FL). In a recent international classifi cation study on NHL in south--eastern Europe, the most common type of NHL was DLBCL (37%), followed by FL (20.2%) 4 . In this study, CLL was included as NHL with a prevalence of 12.5%.
Bendamustine belongs to a group of alkylating agents, however, it has a distinct pharmacodynamic profi le 5 . In vitro, it phosphorylates tumor suppressor p53 leading to apoptosis. Second mechanism is DNA repair by upregulation of EXO1 gene leading to a base excision repair pathway response. Th ird mechanism is inducing mitotic catastrophe causing downregulation of several genes involved in mitotic checkpoints leading to multinucleation or micronucleation and chromatin condensation (all events as hallmarks of mitotic catastrophe). It is important to note that the mechanism of bendamustine action still is not known and additional studies are needed to defi ne the precise pharmacodynamic profi le. Bendamustine also has a favorable pharmacokinetic profi le regardless of sex, age and race 6 . Concerning hepatic dysfunction, no diff erence in pharmacokinetics has been found between normal function and mild hepatic impairment. Data on severe and moderate hepatic impairment are scarce, so caution is warranted when using bendamustine in this patient subpopulation. Concerning renal impairment, diff erence in the safety profi le is not of clinical concern 7 . Patients with renal impairment defi ned as creatinine clearance <40 mL/min had only two higher adverse events, i.e. blood urea nitrogen and thrombocytopenia. Th ese data are further supported by excellent tolerability in multiple myleoma patients with renal dysfunction treated by bendamustine 8, 9 . Historically, bendamustine was fi rst synthesized and used in Eastern Germany during the Soviet era, but with the fall of the Berlin Wall, further research made it available worldwide.
Th e main aim of this review is to assess data on the activity of bendamustine alone or in combinations in NHLs and CLL.
Bendamustine as First Line Th erapy in NHL: the End of CHOP-R Era?
Anthracycline-based regimen in combination with rituximab, so called CHOP-R regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) has been the mainstay of treatment in CD20 positive NHLs [10] [11] [12] . Based on in vitro studies where bendamustine produced apoptotic features in cell lines of indolent lymphomas and synergistic activity with rituximab, it has been established as a possible target drug in indolent NHLs, especially FL 13, 14 . First frontline study examining bendamustine in combination with rituximab (B-R) versus CHOP-R regimen in indolent NHLs was performed by the Stil group for indolent lymphomas 15 . It was a phase III non-inferiority randomized clinical trial which included 549 patients with high tumor burden indolent NHLs and mantle cell lymphoma (MCL) randomized at a 1:1 ratio to receive either CHOP-R or B-R regimen for up to 6 cycles (dose of bendamustine 90 mg/m 2 on days 1 and 2). Despite the non-inferiority design, improvement of progressionfree survival (PFS) favored B-R with median PFS of 69.5 months as compared with only 31.2 months for CHOP-R. Additional analysis was based on histology. In FL, PFS in the B-R arm was not reached as compared with 40.9 months in the CHOP-R arm. Interestingly, B-R outperformed CHOP-R in MCL (35.4 vs. 22.1 months), which is important since the addition of rituximab to CHOP regimen never showed advantages in terms of long-term outcomes in these patients 16 . However, overall survival (OS) did not differ between the groups, with median not being reached. One reason may have been short follow-up and small number of events in both arms. Another and more probable reason lies in the cross-over design of the study, i.e. the patients that progressed during or after CHOP-R regimen were salvaged by B-R (N=116). B-R was also characterized by a distinct toxicity profi le. Concerning hematologic adverse events, lower rates of leukopenia and neutropenia were observed with consequent lower rates of infectious episodes (37% vs. 50%). Concerning non-hematologic events, virtually no alopecia was observed in B-R group with lower rates of paresthesia, which are vincristine-induced in CHOP-R protocol, and stomatitis. On the other hand, skin erythema and skin allergic reaction were more pronounced in B-R group (16% and 15%, respectively).
Another large study in this setting was the BRIGHT non-inferiority study on 447 patients comparing B-R (dose of bendamustine 90 mg/m 2 on days 1 and 2) to CHOP-R or CVP-R (rituximab, cyclophosphamide, vincristine and prednisone) regimens in indolent NHLs or MCL, up to 6 cycles with additional 2 cycles permitted per investigator discretion 17 . Primary objective was complete response (CR) as measured by the "revised response criteria for malignant lymphoma" 18 . CR response was achieved in 31% of B-R group compared to 25% in CHOP-R/CVP-R group, although the diff erence was not statistically signifi cant. Overall response rate (ORR) was similar between the groups (97% and 91%, respectively). In further analysis, all variables favored B-R regimen with MCL being once again the most prominent one. Concerning safety profi le, B-R regimen produced fewer hematologic adverse events, primarily, leukopenia, neutropenia and lymphocytopenia. Th e rates of infections were similar between the groups. Once again, B-R did not cause alopecia. Drug hypersensitivity was noted in B-R group, mainly in the form of skin reactions, but this toxicity was manageable. At the time of writing this review, no data on PFS and OS in the BRIGHT study were available. Interestingly, B-R regimen was better tolerated than CHOP-R or CVP-R as measured by quality of life (QoL) questionnares 19 . Patients reported improved outcomes on many scales such as cognitive, physical, social and emotional functioning, indicating major QoL improvement in patients receiving B-R.
In conclusion, B-R has demonstrated equal or better eff ect to the standard of care, improvement in outcomes in terms of PFS, major improvement in MCL histology, distinct but favorable toxicity profi le, and better tolerability. Th is has led some authors to declare the end of the CHOP-R era in indolent lymphomas 20 . Th e results of these two studies are summarized in Table 1 .
However, despite these encouraging results, regulatory agencies did not recognize B-R as a standard of care in indolent NHLs or MCL 21, 22 . In the USA, bendamustine is approved for rituximab resistant indolent NHL, whereas in the European Union (EU) only some countries such as Germany or the United Kingdom have approved it for fi rst line treatment of indolent NHLs. In Croatia, bendamustine is approved for rituximab-resistant indolent NHLs 23 . In accordance with the leading guidelines and data from two phase III randomized controlled trials, B-R should become standard of care in the treatment of indolent NHLs, especially for MCL patients who are not fi t for high dose chemotherapy [24] [25] [26] . Despite this regulatory limitation, B-R is slowly but steadily entering clinical practice all over the world, replacing the CHOP-R regimen in indolent NHLs.
However, none of the pivotal studies had maintenance strategy with rituximab in protocol. Maintenance with rituximab every 2 months in case of CR or partial remission (PR) has become the standard of care in Europe based on PRIMA results showing improved 3-year PFS of 74.9% in maintenance group compared with 57.6% in observation group 27 . To address this question, the MAINTAIN trial was designed 28 . Th is was a phase III trial with three arms comparing rituximab maintenance for 2 years, 4 years, and observation after B-R induction. Th is approach showed feasibility and no safety signal was noted in preliminary analysis 29 . However, initial results in subset analysis of 120 MCL patients were disappointing 30 . After median follow-up of 54.2 months, two groups did not diff er in PFS (not reached vs.54.7 months) or OS. Th e authors conclude that the follow-up was too short to present defi nitive results. Until then, maintenance strategy following B-R in indolent NHLs or MCL is purely experimental.
Furthermore, in the era of B cell receptor (BCR) signaling, B-R is attractive backbone regimen for combinations with this inhibitor. Yet, we have learnt a lesson in a hard way with idelalisib, a PI3Kδ inhibitor approved for refractory indolent NHLs 31 . In fi rst line setting, it was combined with B-R in the treatment of indolent NHLs or CLL. Despite excellent response rates, the studies were terminated due to unexpected toxicity aff ecting survival curve (cytomegalovirus reactivation, Pneumocystis jirovecii infections, colitis, trans- Concerning DLBCL, to our knowledge, there is no published study evaluating B-R in fi rst line setting, although a phase II trial is ongoing evaluating feasibility of this approach in elderly patients with previously untreated DLBCL 33 .
Bendamustine in Relapsed Setting

Indolent NHLs or MCL
Th ere is only one randomized phase III trial evaluating B-R (dose 90 mg/m 2 ) versus fl udarabine based regimen (FR, dose of fl udarabine 25 mg/m 2 on day 1-3) 34 . Th e study included 219 patients with indolent NHLs or MCL, randomized at a 1:1 ratio. Th e primary objective was PFS, favoring B-R regimen with 34.2 months compared to only 11.7 months in F-R group. Th e authors demonstrated better OS for B-R group (109.7 months and 49.1 months, respectively). B-R and F-R had a similar toxicity profi le, myelosuppression and infections. Th e importance of this trial is that B-R was highly active in relapsed setting and could be used as a retreatment strategy in relapsed or refractory indolent NHLs and MCL 25 . Other single arm trials evaluating B-R regimen in this setting are summarized in Table 2 .
In conclusion, B-R regimen is a viable option in the treatment of patients with relapsed indolent NHLs and MCL not fi t for stem cell transplant with high ORR rates, adequate duration of response and manageable toxicity.
Th ere are multiple trials under way exploring addition of other agents such as lenalidomide, bortezomib, duvelisib (dual PI3Kδ and γ inhibitor) or temsirolimus to enhance the activity of B-R regimen itself [39] [40] [41] [42] .
Bendamustine in rituximab-refractory indolent NHL
Eventually, a signifi cant proportion of patients will develop refractoriness to rituximab defi ned as stable disease (SD) or progressive disease (PD) after rituximab therapy or progression during the fi rst 6 months after completion of therapy. Traditionally, these patients had poor outcomes and represented clinical challenge for treatment strategy.
One study explored bendamustine (dose 120 mg/ m 2 ) in 76 patients with rituximab-refractory indolent or transformed NHL 43 . Th e proportion of patients with transformed NHL was 20%. ORR for the whole group was 77% with 34% CR. ORR for indolent NHLs was 82% with 17 CR and median PFS of 8.25 months. However, duration of response in transformed NHLs was much shorter with PFS being only 4.18 months.
Th e pivotal study in this area was conducted by Kahl et al. including 100 patients with rituximab-resistant NHLs 44 . Th e median number of previous therapies was 2 with 36% of patients being refractory to previous therapy. Bendamustine was administered as a single agent at a dose of 120 mg/m 2 on days 1 and 2 for up to 8 cycles. ORR for the whole group was 77%. Interestingly, bendamustine produced high-level response in chemorefractory group (ORR=64%) and alkylator-refractory group (ORR=60%) due to its noncross resistant properties. However, duration of response was rather short being 9.2 months with median PFS of 9.3 months. Th is study led to approval of bendamustine under current designation in the USA and Croatia 21, 23 . Recently, great breakthrough was achieved in this setting with results of the GADOLIN study 45 . Th is phase III trial explored whether the addition of obinutuzumab, a type II antiCD20 antibody, to bendamustine (90 mg/m 2 on day 1 or 2) followed by maintenance was superior to bendamustine alone. It should be noted that the design of the study was unbalanced since patients in the comparator arm received bendamustine in a dose of 120 mg/m 2 on day 1 or 2. A *addition of mitoxantrone to B-R regimen; **only MCL patients; NHL = non-Hodgkin lymphoma; MCL = mantle cell lymphoma; B = bendamustine; R = rituximab; ORR = overall response rate; PFS = progression-free survival total of 396 patients were randomized at the 1:1 ratio. Despite similar ORR between the groups (69.1% vs. 63%), PFS was signifi cantly diff erent and not reached in G-B group compared to 14 months in B group after median follow-up of 20 months. Th is effi cacy of G-B regimen to produce lasting responses may be attributed to eradication of minimal residual disease (MRD) 46 . In subanalysis of 93 patients, eradication of t(14;18), a pathognomonic event in FL, was associated with improved outcome, with 82% of patients achieving negativity in G-B group compared to 43% of patients in B group. PFS in patients that achieved MRD negativity in G-B group was not reached as compared with 7.6 months in B group. Outcomes of MRD positive patients were poor regardless of the treatment arm, with PFS of 5.4 months in G-B group and 3 months in B group. Th e GADOLIN trial subsequently led to approval of obinutuzumab in combination with bendamustine for rituximab-refractory indolent NHLs 47 . It is important to note that this drug has not yet been approved in the EU for this indication 48 . Th e studies are summarized in Table 3 . Owing to excellent outcomes in rituximab-resistant indolent NHLs, the G-B regimen might be included in the standard of care of this hard-to-treat population. not candidates for high dose chemotherapy and the standard of care remains elusive in this population 51 . Owing to its properties, mainly as alkylator non-cross resistant and favorable toxicity profi le, bendamustine may be the drug of choice in this setting. Several phase II trials evaluated the activity of B-R regimen in relapsed or refractory DLBCL. Th e largest trial included 69 patients receiving B-R (dose of bendamustine 120 mg/m 2 on day 1 or 2) 52 . Th e ORR was high (62.7%) with 37.3% of CR, but the response did not translate in PFS, which was only 6.7 months. All published studies on B-R regimen in relapsed or refractory DLBCL are summarized in Table 4 . 
Is there a role for bendamustine in relapsed or refractory DLBCL?
In young fi t patients with relapsed or refractory DLBCL, high dose chemotherapy combined with rituximab followed by ASCT represents a standard of care 49, 50 . However, a signifi cant subset of patients are
In conclusion, there are limited data on B-R activity in relapsed or refractory DLBCL. B-R regimen results in relatively high ORR, but long term outcomes are poor. Th is regimen should be off ered to a limited number of patients in whom more aggressive therapy is not a valid option due to comorbidities. Furthermore, this regimen based on data from phase II trials should not be pursued further in the treatment of DLBCL, especially in the era of BCR inhibitors 55 .
Bendamustine in CLL
Bendamustine in the treatment of CLL; fi rst line setting Due to demonstration of in vitro effi cacy of bendamustine in CLL cell lines, it has become an attractive agent in the treatment of CLL 56 . Th e pivotal study in this area is comparison of bendamustine (100 mg/m 2 on days 1 and 2) to chlorambucil (0.8 mg/kg on days 1 and 15) in 319 patients for up to 6 cycles 57 21, 23 . Based on in vitro studies and activity in indolent NHLs, the question arises if bendamustine could be the backbone chemotherapy in combination with rituximab 14 . Th e preliminary data come from phase II trial on 117 patients with untreated CLL 59 . B-R (dose 90 mg/m 2 on days 1 and 2) resulted in impressive ORR of 88% with 23.1% of CR. Th e median eventfree survival (EFS) was 33.9 months with the majority of patients being alive at the end of follow-up. However, we must note that ORR (37.5%) was lower in patients harboring ominous del(17p), indicating that B-R is not an appropriate regimen for this subpopulation. Th ere is an ongoing phase III MaBLe study comparing B-R to R-Chl, for which defi nitive results were not available at the time of writing this review 60 . Yet, due to the fact that bendamustine was compared to chlorambucil, a 'sick young puppy' as the world renowned expert Bruce Cheson would call it, comparison with FCR, the standard of care in young, fi t patients without del(17p) was needed 61, 62 . To address this question, the CLL 10 study was designed including 561 young fi t patients without del(17p) as non-inferiority study comparing B-R (dose 90 mg/m 2 on days 1 and 2) to FCR for up to 6 cycles 63 . Primary endpoint was PFS of 41.7 months in B-R compared to 55.2 months in FCR group, indicating that B-R was inferior in this setting. ORR was similar between the groups (95% vs. 96%), with a higher rate of CR in FCR group (31% vs. 96%). However, the treatment with FCR comes with multiple adverse events, mainly hematologic toxicities, leading to a greater rate of infections (77% vs. 65%). Furthermore, FCR causes prolonged myelosuppression with the possibility of late infections after completion of therapy 64 . Another safety signal in FCR is the occurrence of secondary malignancies with a 2.38 risk to develop therapy-related acute myelogenous leukemia or myelodysplastic syndrome (5.1%) or Richter transformation to DLBCL (9%) 65 . Both entities are associated with dismal outcomes.
In our opinion, despite being inferior to FCR, B-R regimen should be introduced in the real-world clinical setting. Th e basis of treatment should be made upon specifi c goals and patient comorbidities, i.e. the choice of B-R regimen should be made individually in fi rst line setting of CLL.
Recently, feasibility of obinutuzumab in combination with FC (fl udarabine, cyclophosphamide) or bendamustine in a dose of 90 mg/m 2 (G-B) was explored in the Galton phase IB study 66 . Th e number of patients in G-B group was 20 with impressive ORR of 90% with 20% CR and 25% CR with incomplete marrow recovery. After median follow-up of 23.5 months, none of the patients progressed or died. Th e safety profi le was manageable with most prominent adverse effect being infusion related reaction in 90% of patients, occurring primarily at fi rst G-B cycle. Based on the effi cacy of this regimen, a phase II trial is currently ongoing evaluating G-B in previously untreated CLL 67 . Bendamustine was also investigated in combination with ofatumumab, human antiCD20 antibody leading to cell lysis and antibody-dependent cell-mediated cytotoxicity 68 . Th is drug was fi rstly approved in the EU for the treatment of patients refractory to fl udarabine and alemtuzumab 69 . In a study on 40 previously untreated patients unsuitable for FCR chemotherapy, the ORR was 95% with 43% CR 70 . Toxicity profi le was tolerable with infusion reactions being the most common adverse event. Th e pivotal study in this area is the OMB11 5991 study on 44 patients not fi t enough for FCR regimen 69 . ORR was 95% with 43% CR. It is important to note that more than half of the patients achieved MRD negativity, i.e. B-R can achieve molecular response. Th is led to approval of this regimen in patients who are not fi t enough to tolerate FCR protocol 68 . However, we must note that due to the clear superiority of rituximab and its worldwide use, ofatumumab is rarely used in clinical practice and the real impact of these regimens in everyday use remains unknown. Th e results of studies described above are summarized in Table 5 .
Bendamustine in the treatment of CLL; relapsed setting
Th e earliest trial in this setting was a dose fi nding trial in 15 patients with relapsed or refractory CLL 71 . Th e maximum tolerated dose was 110 mg/m 2 and the recommended dose was 100 mg/m 2 at four-week interval. Th e activity was promising with nine patients responding to treatment including 4 CRs. During the 15-month follow-up, only one patient relapsed. Th e authors concluded that this regimen was active and tolerable in heavily pretreated CLL and should be investigated further on a larger number of patients.
A larger phase II study included 78 patients treated with B-R regimen (dose 70 mg/m 2 on day 1 or 2) 72 . ORR was 50% with 9% CR and 47.4% PR. In subgroup analysis, patients with del(17p) had the worst outcome with ORR being only 7.1%. It is important to note that ORR was high in fl udarabine-resistant patients (45.5%). Th e median EFS was 14.7 months after 24-month follow-up. Th e median OS was 33.9 months. Th e regimen was associated with more toxicity than in the fi rst line setting. Th e adverse events of concern were severe infections that occurred in 12.8% of patients, but this toxicity profi le is expected in heavily pretreated patients.
In the Italian phase II trial, 47 patients were enrolled receiving bendamustine (dose 70 mg/m 2 on day 1 or 2) in combination with ofatumumab for up to 6 cycles 73 . B-O regimen resulted in ORR of 72.3% with 17% CR. It also yielded somewhat better ORR of 30% CLL = chronic lymphocytic leukemia; B = bendamustine; B-R = bendamustine-rituximab; B-O = bendamustine-ofatumumab; ORR = overall response rate; PFS = progression-free survival; OS = overall survival; EFS = event-free survival; NA = not applicable in del(17p) subgroup. After median follow-up of 24.2 months, 2-year OS and PFS rates were 83.6% and 49.6%, respectively. However, most interesting is the addition of ibrutinib, an oral Bruton kinase inhibitor to B-R regimen in the phase III Helios study 74 ; 578 patients were assigned to receive either placebo or ibrutinib in addition to B-R (dose 70 mg/m 2 on day 1 or 2) for up to 6 cycles. Ibrutinib was administered until disease progression or unacceptable toxicity. Th e main objective was PFS, which was not reached in ibrutinib group as compared with 13.3 months in placebo group. ORR was higher in ibrutinib group (83% vs. 68%). In post hoc analysis, all variables favored ibrutinib treatment. Th e addition of ibrutinib did not result in additional safety signals. One of the possible pitfalls of the study was not including patients with del(17p) for which ibrutinib has become the standard of care [75] [76] [77] .
In conclusion, B-R regimen seems like a reasonable option in patients failing FCR. Concerning the addition of ibrutinib to B-R, we must wait for reaction of regulatory agencies, i.e. whether ibrutinib will be registered in combination with B-R for the treatment of relapsed or refractory CLL. All the studies are summarized in Table 6 .
Conclusion
As shown above, bendamustine alone or in combinations with other agents has shown impressive activity in indolent NHLs, MCL and CLL without del(17p). We must highlight certain combinations which may be a standard of care in various settings of these diseases, as follows:
1. B-R for fi rst line setting in indolent NHLs or MCL, 2. G-B for rituximab-resistant indolent NHLs, 3. B-R for selected patients with CLL without del(17p), and 4. B-R in combination with ibrutinib for relapsed CLL without del(17p). However, we are in the era of BCR pathway inhibitors, so the question arises whether bendamustine is still relevant while pursuing the 'chemo-free' era. However, these agents have shown unexpected toxicities, especially in fi rst line setting, leading to early termination of multiple trials and causing 'speed bumps' on our way to 'chemo-free' era 78 . Until we learn how to combine these inhibitors with acceptable toxicity profi le, bendamustine will remain relevant in every day hematologic practice. 
